Jannik Prasuhn1,2, Meike Kasten1,3, Melissa Vos1, Inke R König4, Sebastian M Schmid5,6, Britta Wilms5,6, Christine Klein1, Norbert Brüggemann1,2. 1. Institute of Neurogenetics, University of Lübeck, Lübeck, Germany. 2. Department of Neurology, University Medical Center Schleswig-Holstein, Lübeck, Germany. 3. Department of Psychiatry and Psychotherapy, University Medical Center Schleswig-Holstein, Lübeck, Germany. 4. Institute of Medical Biometry and Statistics, University of Lübeck, Lübeck, Germany. 5. Institute of Endocrinology and Diabetes, University of Lübeck, Lübeck, Germany. 6. German Center for Diabetes Research (DZD), Neuherberg, Germany.
Abstract
Background: Despite rapid advances in research on Parkinson's disease (PD), in particular in the elucidation of genetic contributions, no disease-modifying therapy has become available to date. Objectives: In the proposed project, we aim to investigate the potential effects of vitamin K2 (long-chain menaquinone 7, MK-7) in genetically determined PD with mitochondrial dysfunction. Methods: A total of 130 study participants (26 biallelic Parkin/PINK1 mutation carriers, 52 sporadic PD patients, and 52 healthy controls) will receive the trial medication (MK-7 or placebo for 1 week). 31P-Magnetic resonance spectroscopy imaging of the forebrain and basal ganglia (31P-MRSI, primary endpoint) as well as other advanced neuroimaging methods, clinical assessment, including quantitative movement analysis, and biomarker sampling will be applied pre- and post-intervention. Innovation: The proposed project is highly translational as it builds on compelling mechanistic data from animal studies as well as on a small preliminary data set in humans. Patients are selected based on their mutation-related mitochondrial dysfunction and compared to disease and a healthy control group in a personalized medicine approach. We will further investigate how neuroimaging and blood-derived biomarkers can predict individual treatment response in sporadic PD. Clinical trial registration: This study was registered at the German Clinical Trial Registry (DRKS, DRKS00019932) on the 19th of December 2019.
RCT Entities:
Background: Despite rapid advances in research on Parkinson's disease (PD), in particular in the elucidation of genetic contributions, no disease-modifying therapy has become available to date. Objectives: In the proposed project, we aim to investigate the potential effects of vitamin K2 (long-chain menaquinone 7, MK-7) in genetically determined PD with mitochondrial dysfunction. Methods: A total of 130 study participants (26 biallelic Parkin/PINK1 mutation carriers, 52 sporadic PDpatients, and 52 healthy controls) will receive the trial medication (MK-7 or placebo for 1 week). 31P-Magnetic resonance spectroscopy imaging of the forebrain and basal ganglia (31P-MRSI, primary endpoint) as well as other advanced neuroimaging methods, clinical assessment, including quantitative movement analysis, and biomarker sampling will be applied pre- and post-intervention. Innovation: The proposed project is highly translational as it builds on compelling mechanistic data from animal studies as well as on a small preliminary data set in humans. Patients are selected based on their mutation-related mitochondrial dysfunction and compared to disease and a healthy control group in a personalized medicine approach. We will further investigate how neuroimaging and blood-derived biomarkers can predict individual treatment response in sporadic PD. Clinical trial registration: This study was registered at the German Clinical Trial Registry (DRKS, DRKS00019932) on the 19th of December 2019.
Authors: Ronald B Postuma; Daniela Berg; Matthew Stern; Werner Poewe; C Warren Olanow; Wolfgang Oertel; José Obeso; Kenneth Marek; Irene Litvan; Anthony E Lang; Glenda Halliday; Christopher G Goetz; Thomas Gasser; Bruno Dubois; Piu Chan; Bastiaan R Bloem; Charles H Adler; Günther Deuschl Journal: Mov Disord Date: 2015-10 Impact factor: 10.338
Authors: Lisa Holper; Martin J Lan; Patrick J Brown; Elizabeth M Sublette; Ainsley Burke; John J Mann Journal: Depress Anxiety Date: 2019-05-21 Impact factor: 6.505
Authors: Karen Otte; Bastian Kayser; Sebastian Mansow-Model; Julius Verrel; Friedemann Paul; Alexander U Brandt; Tanja Schmitz-Hübsch Journal: PLoS One Date: 2016-11-18 Impact factor: 3.240